Pharmaceutical composition on the basis of Stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo

Abstract

This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W / O and O / W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application is the U.S. National Phase of International Patent Application Serial No. PCT / BR2007 / 000316, filed on Nov. 14, 2007, which claims priority to Brazilian Patent Application Serial No. PI07007671, filed on Feb. 15, 2007, both of which are hereby incorporated by reference in their entireties.[0002]This invention generally refers to the obtention of a compound and a standard pharmaceutical product from roots, stems, barks, and leaves of plants of the Stachytarpheta (Verbenaceae family) genus, in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis or semi-synthesis, used alone (pure extract) or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W / O and O / W (creams and gels), liposomes, m...

AI Technical Summary

Benefits of technology

[0006]Recent researches have demonstrated the existence of specific biochemical failures on the catalase activity and an accumulation of hydrogenated peroxide in the skin of vitiligo patients. The catalase suggests that keratinocytes in vitiligo are capable of recycling the 5, 6, 7, 8-tetrahydrobiopterin (6-BH4), an adjuvant factor for the hydroxylation of L-phenylalanine into L-tyrosine. This may break the supply of L-thyroxine for the melanin production, increasing the catecholamine by the keratinocytes, resulting in the accumulation of toxic free radicals that may damage the melanocytes.

[0010]Use of melagenine: it helps decreasing the patches in 75% of the patients.

[0020]The species used in this invention are more easily found in nature than Stachytarpheta polyura, mentioned on the prior art, in larger quantities, as well as larger sizes, increasing the feasibility of the production in industrial scale. Such species, popularly known as gervão, gerbão, overjão, chá-do-Brasil (“verbena / vervain”), among other popular names, are used in the traditional medicine as cicatrizant, treatment for stomach problems and antifebrile.

Problems solved by technology

This may break the supply of L-thyroxine for the melanin production, increasing the catecholamine by the keratinocytes, resulting in the accumulation of toxic free radicals that may damage the melanocytes.

Use of Diprosalic: Diprosalic solution, less efficient than melagenine, is topically used on the patches.

In light of the foregoing, it was demonstrated that the existing treatments are not satisfactory to fight vitiligo manifestations.

This species, Stachytarpheta polyura, is rarely found in nature, and its diminutive size makes the production of the extract in industrial scale unfeasible, costly and unprofitable.

Images